郑州透明肺段模型南昌穿戴式四肢止血训练套件,贵阳高级多功能护理急救训练模拟人（心肺复苏、基础护理男女导尿、手臂静脉穿刺及肌肉注射）,成都马解剖模型,南宁1/2标准模型,滁州肺段模型,阜新足关节剖面模型,昆明高智能数字网络化ICU（综合）护理技能训练系统

The Cambridge Analytica?scandal has thrust Facebook privacy settings into the national conversation after the political firm used the personal data of about 50 million people without their consent.Now, Mozilla is helping Firefox users keep their Facebook data secure so they won't be exploited in the future.The company has introduced a Firefox extension that it says will make it much harder for Facebook to track which websites you browse.Facebook has developed a network of trackers that tell the social media site which of its users are visiting certain webpages, like online retailers. Facebook will then use that information to serve its users ads based on what products they've been viewing.Mozilla says its Facebook Container extension will make it much more difficult to track which websites you visit, and keep your browsing information private.Mozilla admits the extension isn't perfect. In a blog post, the company said that the extension would not have prevented user information from being abused in the Cambridge Analytica scandal. It also says that Facebook Container would not work well on sites which require you to use Facebook information to log in.But Mozilla says the simple step of downloading the extension is giving power back to internet users. "Troves of data are being collected on your behavior on the internet, and so giving users a choice to limit what they share in a way that is under their control is important," the company wrote.To download Facebook container, first download the free Mozilla Firefox browser if you're not already using it. Then, all you need to do is click this link and add the extension.Alex Hider is a writer for the E.W. Scripps National Desk. Follow him on Twitter @alexhider. 1763

The family of a Pennsylvania woman who died in jail in 2015 from heroin withdrawal symptoms was awarded .75 million in a wrongful death suit settlement this week, CBS News reported. Victoria "Tori" Herr, then 18, died on April 5, 2015, nine days after being arrested after police found drugs in the woman's apartment. Herr told police that she had consumed 10 bags of heroin a day. During her first four days in custody, Herr reportedly suffered from bouts of vomiting and diarrhea. She was treated with water and Ensure, but was unable to keep her fluids down. The result of those symptoms led her to cardiac arrest and to lose consciousness, CBS News reported. Herr's lawyers claimed that the Lebanon County Correctional Facility did not meet her basic medical needs, and then lied. "Anyone who looked at her would have known that she was very sick and that she needed attention," Herr's family lawyer Jonathan Feinberg told CBS. "There was a complete disregard for her needs, which can only be tied back to the fact that she was addicted to drugs."As part of the multi-million-dollar settlement, the jail's warden, nurses and other employees agree that there was no wrongdoing. To read CBS News' full report, click here.  1284

The fourth nor'easter in three weeks already is closing schools and canceling thousands of flights Wednesday as it's expected to dump record springtime snow in the Northeast.A day after the official beginning of spring, the storm will bring heavy snow, strong winds and even coastal flooding to some areas. It has potential to be one of the most significant and most disruptive snowstorms this late in the season, CNN meteorologists said."If the current forecast pans out, this nor'easter will dump more snow on Washington, Philadelphia and New York than the three earlier storms combined," CNN meteorologist Brandon Miller said.More than 70 million people are under a winter storm watch, warning or advisory from the southern Appalachians to Boston.The storm will move away from the region by Thursday but not without first hitting coastal New England and Maine.Latest developments? More than 4,100 flights are canceled Wednesday due to the storm, according to the tracking site Flightaware.com.? Public schools in New York City, Philadelphia and the District of Columbia are closed Wednesday.? The storm already dumped 13 inches of snow in Greencastle, Pennsylvania, and blanketed Smith Crossroads in West Virginia with 9.2 inches.Snow disrupting nation's capitalWashington will likely see 4 to 6 inches of snow, with some models hinting at much higher totals for the District. Areas west and north of the city are likely to see close to a foot of snow."It's been 75 years since Washington has had 5 inches of snowfall or greater this late in the season," Miller says.Track the storm with high resolution auto-updating graphicsThe inclement weather caused closures for much of the federal government. The White House and State Department canceled all public events for the day. However, the House and Senate are planning to work Wednesday as Congress tries to finalize a spending deal.Philadelphia could see up to a foot of snow. The City of Brotherly Love may get its biggest snowfall after the first day of spring in more than 100 years.For those in other parts of Pennsylvania, the storm was already well underway Wednesday morning. Thile Kreider posted an Instagram video of the snow blanketing her yard in Manheim.New York could break 1958 recordWind gusts and snow reached New Jersey and New York City on Wednesday morning. Ten inches to more than a foot is forecast in the New York City area before the storm departs early Thursday.But Central Park in Manhattan may only receive 4 to 6 inches of snow, CNN meteorologist Chad Myers said, explaining it's more likely snow will accumulate in areas at higher elevations."If New York gets 12 inches of snow -- the National Weather Service currently has a high-end potential of 13 to 21 inches -- it would be its largest snowfall ever recorded after the first day of spring," Miller says.The current record is 11.8 inches, set on March 21, 1958.With these late winter storms, it is difficult to predict snowfall amounts because of the mixing of warmer air. In some of the earlier nor'easters, the air near the ground has stayed warm enough that places like New York have seen lots of snow fall from the sky but had little accumulation. An urban heat island effect is plausible once again with this spring storm.Boston stayed on the warmer side in the first two nor'easters but then got walloped with snow during the third storm this month. The city is likely to see another 6 to 8 inches of snow, adding to the 20-plus inches it has already received in March.If Boston gets 10 inches, the city would have its third snowiest March on record.These late winter storms are likely to become more frequent with climate change. A study last week in the scientific journal Nature Communications ties extreme winter weather, specifically major snowstorms in the Northeast, to warming Arctic temperatures.Blizzard conditions likelyWith a forecast of heavy snow and winds more than 45 mph, blizzard conditions are possible.New York City could see sustained winds of 20 to 30 mph Wednesday, and coastal areas such as Cape Cod in Massachusetts are predicted to receive gusts up to 60 mph from midmorning Wednesday to Thursday.What is makes a snow storm a blizzardFlooding is a threat along the coast from Virginia to Massachusetts. Some of the worst coastal flooding could occur along the Jersey Shore, with high tides of 2 to 3 feet above normal possible.This will put a strain on already vulnerable coastal areas, which saw dramatic storm surges from the nor'easters over the last three weeks.The-CNN-Wire 4555

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The chairwoman of the Republican National Committee, Ronna McDaniel, has tested positive for coronavirus, according to multiple reports.The New York Times reports McDaniel is experiencing mild symptoms and is quarantining in Michigan.She was last with President Donald Trump last Friday, and the NYT says she received her diagnosis on Wednesday. 353